Helix BioMedix Inc
OTC:HXBM
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Helix BioMedix Inc
OTC:HXBM
|
606.7k USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
386.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.1B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.1B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Helix BioMedix Inc
Glance View
Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington and currently employs 8 full-time employees. The company went IPO on 2000-07-25. The firm is focused on drug development for treatment of rare dermatological diseases. The firm's research and development (R&D) consists of a proprietary library of patented bioactive peptides based on the body’s innate immunity. The firm is focused on developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum (XP). HB4208 is a polypeptide DNA Damage Response (DDR) enzyme that is based on cellular repair pathways. HB4208 is in the preclinical development Phase. The firm is also engaged in identifying the precise peptides needed to stimulate cellular processes and control cell wall defense. Using the specific amino acid sequence for the desired activity, the Company's peptides work with targeted precision to provide optimal skin enhancing results in cosmeceutical and over the counter (OTC) formulations. Its peptides include Oligopeptide-10, Palmitoyl Hexapeptide-14 and others.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
Over the last 3 years, Helix BioMedix Inc’s Operating Margin has increased from -843.9% to -117.3%. During this period, it reached a low of -843.9% on Aug 30, 2009 and a high of -100.5% on Mar 31, 2012.
